The global DNA/RNA extraction market is projected to grow from USD 1.7 billion in 2026 to USD 3.42 billion by 2036, registering a 7.1% CAGR during the forecast period. The market was valued at USD 1.61 billion in 2025 and is expected to create an incremental opportunity of approximately USD 1.7 billion through 2036 as genomic research, clinical sequencing, liquid biopsy, and precision medicine programs expand.

Kits and reagents are expected to remain the leading product type, accounting for 61.0% of market share in 2026. Column-based methods hold 43.0% of the method segment, while blood represents the leading sample type with a 50.0% share. Increasing laboratory automation is also shifting procurement toward extraction formats compatible with robotic platforms and high-throughput clinical workflows.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-10543

Why Automated Extraction Matters for DNA/RNA Extraction Companies

The DNA/RNA extraction market is moving beyond predominantly manual, protocol-dependent workflows as laboratories seek greater throughput, consistency, and integration with downstream molecular testing. Hospitals, reference laboratories, biobanks, and research institutions are increasingly adopting standardized extraction kits that can be incorporated into automated workflows.

The expansion of genomic sequencing is creating sustained demand for high-purity nucleic acids. Oncology, rare disease testing, pharmacogenomics, infectious disease diagnostics, and companion diagnostic programs all require reliable extraction from increasingly diverse biological samples.

Automation is becoming particularly important in high-volume laboratories. Magnetic bead-based and column-based extraction formats that integrate with robotic systems can help laboratories process larger sample volumes while reducing manual intervention and workflow variability.

Anurag Sharma, Principal Consultant at Future Market Insights, says, “The DNA/RNA extraction market is moving from manual, protocol-dependent workflows toward automated, kit-standardized processes that support clinical throughput requirements. Companies with integrated extraction-to-sequencing solutions and regulatory-cleared kit platforms are positioned to capture the growing demand from hospital molecular diagnostics and precision medicine programs through 2036.”

Market Snapshot

·         Market Size (2025): USD 1.61 billion

·         Market Size (2026): USD 1.7 billion

·         Forecast Value (2036): USD 3.42 billion

·         CAGR (2026–2036): 7.1%

·         Incremental Opportunity: Approximately USD 1.7 billion

·         Leading Product Type: Kits and reagents – 61.0% share

·         Leading Extraction Method: Column-based – 43.0% share

·         Leading Sample Type: Blood – 50.0% share

·         Fastest-Growing Country: South Korea – 7.4% CAGR

·         Second-Fastest Country: USA – 7.3% CAGR

·         Leading Company: Qiagen N.V. – estimated 22.0% share

The DNA/RNA extraction market is forecast to more than double from USD 1.61 billion in 2025 to USD 3.42 billion by 2036, driven by genomic testing, precision medicine, and laboratory automation.

What's Driving Near-Term Demand?

The expansion of genomic research and clinical sequencing programs is strengthening demand for reliable nucleic acid extraction. Research laboratories and hospital molecular diagnostics departments require extraction systems capable of delivering consistent yields and purity for sequencing and downstream molecular analysis.

Liquid biopsy is another important demand area. Increasing use of blood-based molecular testing is creating requirements for efficient extraction of DNA and RNA from blood and other biological samples. Companion diagnostic testing is similarly increasing the need for validated extraction workflows that can meet clinical and regulatory requirements.

Precision medicine programs across oncology, rare diseases, and pharmacogenomics are further expanding the addressable market. As genomic information becomes more integrated into clinical decision-making, extraction becomes an increasingly important upstream component of the diagnostic workflow.

Automation is also changing procurement priorities. High-throughput laboratories are increasingly looking for extraction platforms and consumables that can integrate with robotic systems, laboratory information systems, and downstream sequencing workflows.

How Are Kits and Reagents Shaping Market Growth?

Kits and reagents are projected to account for 61.0% of the product type segment in 2026, reflecting strong demand for standardized, ready-to-use extraction solutions.

Standardized kits can simplify laboratory workflows by providing predefined reagents, protocols, and consumables for specific sample types or applications. This is particularly relevant to clinical laboratories where reproducibility and validated procedures are important purchasing considerations.

Column-based extraction methods maintain a 43.0% share, supported by established laboratory workflows and reproducible yield performance. At the same time, automated magnetic bead-based systems are gaining relevance in high-throughput environments where robotic compatibility and scalable processing are priorities.

Where Are the Fastest-Growing Country Opportunities?

·         South Korea is projected to lead country-level growth at a 7.4% CAGR, supported by government investment in precision medicine infrastructure and expanding clinical genomics programs.

·         The United States follows at 7.3%, benefiting from large-scale biobank initiatives, clinical sequencing adoption, companion diagnostic testing, and an established molecular diagnostics ecosystem.

·         The market analysis covers the USA, UK, European Union, Japan, South Korea, and 25+ additional countries, providing a broad view of regional demand and competitive opportunities through 2036.

What Challenges Could Constrain Adoption?

Cost sensitivity remains a consideration, particularly for laboratories balancing consumable expenditure against increasing sample volumes. Automated extraction platforms can also require substantial initial investment in instrumentation and workflow integration.

Regulatory requirements present another challenge for clinical applications. Extraction protocols used in companion diagnostics and other regulated workflows may require validated or IVD-cleared solutions, favoring suppliers with established regulatory capabilities.

Sample variability can also affect extraction performance. Blood, tissue, and other biological materials can present different processing requirements, making consistent yield and purity across sample types an important technical consideration.

Laboratory integration represents an additional hurdle. As extraction becomes connected to sequencing, PCR, and other downstream workflows, suppliers must provide systems capable of fitting into increasingly automated and interconnected laboratory environments.

👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-10543

About the Report

Future Market Insights' DNA/RNA Extraction Market report evaluates the industry across product type, extraction method, sample type, application, end user, and region. The study examines market growth linked to genomic research, clinical sequencing, liquid biopsy, companion diagnostics, precision medicine, and laboratory automation.

The report covers the USA, UK, European Union, Japan, South Korea, and 25+ additional countries, with forecasts extending through 2036.

Key Companies Profiled:

·         Qiagen N.V.

·         Thermo Fisher Scientific Inc.

·         Roche Diagnostics

·         Promega Corporation

·         Bio-Rad Laboratories Inc.

·         Agilent Technologies

·         Zymo Research

·         Macherey-Nagel

·         Omega Bio-tek

·         Norgen Biotek

DNA/RNA Extraction Market Report:
https://www.futuremarketinsights.com/reports/dna-rna-extraction-market

FMI Research Methodology:
https://www.futuremarketinsights.com/methodology

About Future Market Insights

Future Market Insights (FMI) is a global market intelligence and consulting firm providing syndicated research, customized research, and strategic consulting across healthcare, biotechnology, pharmaceuticals, technology, chemicals, and other industries. FMI combines market modeling, primary research, competitive analysis, and industry intelligence to support strategic business decisions.

Disclosure: This press release is based on Future Market Insights syndicated research. Market estimates and forecasts may be revised as underlying data, technology adoption, regulatory conditions, and market dynamics evolve.

Media Contact

Future Market Insights, Inc.

Email: sales@futuremarketinsights.com

UK: +44 20 3769 9709

US: +1 347 918 3531